Collaboration Update

Physiomics PLC
12 December 2007


                                 Physiomics plc

The following announcement was released earlier today, 12 December 2007, by
ValiRx Plc.


For further information:

Physiomics plc
Christophe Chassagnole
01865 784 982

Grant Thornton Corporate Finance
Philip Secrett/Colin Aaronson
020 7383 5100

                                   ValiRx Plc
                          ('ValiRx' or 'the Company')

      Physiomics Collaboration Update - Cancer Cell Death Model Developed

ValiRx (AIM: VAL), the cancer therapeutics company, today announces that Phase 1
of its collaboration with Physiomics plc ('Physiomics') (AIM: PYC), the European
systems biology simulation company, has been completed.

Under the collaboration, originally announced in February 2007, Physiomics' In
Silico simulation technology has been successfully coupled with ValiRx's GeneICE
technology to generate a cancer cell death model - the Apoptosis Model.

This model, on which ValiRx believes it should be able to secure a patent, will
be used to accelerate ValiRx's own internal development programmes and as an R&D
tool to be licensed out to third parties.

Already the Apoptosis Model has helped the Company reach key decisions regarding
GeneICE in relation to which new cancer cells to target. For example, it has
helped support the decision to focus on specific hormone resistant cancers.

Dr Satu Vainikka, CEO of ValiRx, commented:

'Systems based biology is able not only to accelerate the R&D process but also
improve diagnostic and prognostic processes. We believe our Apoptosis Model
represents a significant new tool for use within the pharmaceutical industry and
has already received significant industry interest.'

Dr Christophe Chassagnole, COO of Physiomics added:

'We are pleased to have successfully applied our simulation technology to
accelerate the development of ValiRx's breakthrough GeneICE compounds. The
respective strengths of our technologies have synergised to produce significant
gains and we look forward to continuing to work with ValiRx in the future.'


                                   ---Ends---


About ValiRx plc

ValiRx is a biopharmaceutical development company that is building a portfolio
of complementary cancer-related therapeutic and diagnostic technologies. It
currently holds a worldwide exclusive license for Nucleosomics, the early stage
oncology diagnostics technology, and has majority stakes in Cronos Ltd and
ValiBIO SA:

  • Cronos holds worldwide exclusive licenses to two innovative and
    potentially market changing technologies, GeneICE and HyperGenomics, and is
    developing further novel cancer therapies;
  • ValiBIO SA is a Belgium joint venture between ValiRx and Bio.Be focusing
    on the development and commercialisation of products in the epigenomics
    sector, the first products to be put into development being HyperGenomics
    and Nucleosomics. ValiRx has a 77% majority holding in the company.

ValiRx is headquartered in London, England. Further information can be found at
www.valirx.com

About Physiomics plc

Physiomics plc (AIM:PYC) is a computational systems biology services company
applying simulations of cell behaviour to drug development to reduce the high
attrition rates of clinical trials. As 80-90 per cent of all clinical drug
candidates fail to reach the market, estimates1 show that an overall ten per
cent improvement in success rates could reduce the cost of one drug's
development by as much as $242 million, from the current estimate of around $800
million.

Physiomics develops computational systems biology models to predict and
understand cancer drug efficacy from pre-clinical research to clinical
development. Physiomics has created detailed mathematical models incorporating
most important molecular events taking place during the human cell cycle and
apoptosis processes. Physiomics developed SystemCell(R) technology, a
multi-cellular environment software, which enables the simulation of population
of 'virtual cells'.

Physiomics, based in Oxford, UK, was founded in 2001, and floated on AIM in
2004. For further information, please visit www.physiomics-plc.com

SystemCell(R) is a registered trademark of Physiomics plc
1 Tufts Centre Impact Report 2002


Contact Details:

     ValiRx Plc                 WH Ireland             GTH Communications
  Dr Satu Vainikka            David Youngman      Toby Hall / Jade Mamarbachi
[phone]       [phone]       [phone]


                      This information is provided by RNS
            The company news service from the London Stock Exchange